title: Drug discovery for the treatment of leishmaniasis, African sleeping sickness and Chagas disease.
abstract: The trypanosomatid protozoa Leishmania, Trypanosoma brucei and Trypanosoma cruzi are the caustive agents of the human diseases respectively, leishmaniasis, African sleeping sickness and Chagas disease. Among the 17 'neglected tropical diseases' highlighted by WHO, progress towards the treatment of these diseases has improved in recent decades, as a result of increased awareness, the emergence of public-private research partnerships and advances in drug-discovery technologies and techniques. Despite this, the current therapies for these diseases have serious shortcomings and, as such, the need to develop novel drugs, improve diagnosis and control the spread of disease is of paramount importance. Future Medicinal Chemistry invited leading experts in the field to share their thoughts and opinions on the changing face of drug discovery in the pursuit of treatments for trypanosomatid-based diseases.
mesh_terms: D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D014355:Chagas Disease / Q000175:diagnosis / Q000188:drug therapy*; D004353:Drug Evaluation, Preclinical; D057166:High-Throughput Screening Assays; D006801:Humans; D007896:Leishmaniasis / Q000175:diagnosis / Q000188:drug therapy*; D055818:Public-Private Sector Partnerships; D014353:Trypanosomiasis, African / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000981:Antiprotozoal Agents